Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
CellZome
company
About
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- €30M
- Industries
- Biotechnology,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Close
CellZome is a pharmaceutical company that discovers, develops, and commercializes kinase-targeted drugs for the treatment of inflammatory diseases. It develops a pipeline of kinase inhibitors targeting inflammatory mediators as oral therapeutics for rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.CellZome was founded in 2000 and is based in Heidelberg, Baden-Wurttemberg.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€30M $31M
CellZome has raised a total of
€30M $31M
in funding over 2 rounds. Their latest funding was raised on
Mar 17, 2003 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 17, 2003 | Series C | €30M | 2 | — | — | Detail |
| Mar 1, 2001 | Series B | $31M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
CellZome is funded by 2 investors.
Advent International
and Biofrontier Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advent International
|
— | Series C |
Biofrontier Partners
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
